By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, announced financial results for the second quarter ended June 30, 2014. The Company also provided an update on its development programs for ThermoDox(®), its proprietary heat-activated liposomal encapsulation of doxorubicin, and two newly acquired technology platforms, TheraPlas™ and TheraSilence™, in immunotherapy and RNA delivery (see also Celsion Corporation).
"Our significant progress over the past quarter is consistent with our previously stated objectives and has established a new growth trajectory for Celsion. With multiple opportunities to create long-term value for our shareholders, Celsion represents a development company of unique proportions," said Michael Tardugno, Celsion's President and Chief Executive Officer. "With our recent acquisition of EGEN, we have created a fully-integrated oncology company with a multi-phase pipeline of chemotherapies, immunotherapies and DNA or RNA-based therapies. We are now focused on successfully executing our Phase III OPTIMA Study for ThermoDox(®) plus optimized radiofrequency ablation in primary liver cancer. We will also be working to leverage the potential of ThermoDox(®) in additional indications, and advancing development of our newest clinical asset, EGEN-001, in both ovarian cancer and glioblastoma."
Keywords for this news article include: Oncology, Celsion Corporation, Investment and Finance.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC